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Abstract
Background
Schistosomiasis is a widespread public health concern in the poorest regions of the world.
The principal control strategy is regular praziquantel administration to school-aged children
in endemic areas. With calls for the elimination of schistosomiasis as a public health prob-
lem, expanding praziquantel delivery to all community members has been advocated. This
systematic review and meta-analysis compares the impact of community-wide and child-tar-
geted praziquantel distribution on schistosomiasis prevalence and intensity in school-aged
children.
Methodology/Principal findings
We searched MEDLINE, Embase and Web of Science to identify papers that reported schis-
tosome prevalence before and after praziquantel administration, either to children only or to
all community members. Extracted data included Schistosoma species, drug administration
strategy, number of treatment rounds, follow-up interval and prevalence and intensity before
and after treatment. We used inverse variance weighted generalised linear models to exam-
ine the impact of mass versus targeted drug administration on prevalence reduction, and
weighted boxplots to examine the impact on infection intensity reduction. This study is regis-
tered with PROSPERO, number CRD42018095377.
In total, 34 articles were eligible for systematic review and 28 for meta-analysis. Schisto-
soma mansoni was reported in 20 studies; Schistosoma haematobium in 19 studies, and
Schistosoma japonicum in two studies. Results of generalised linear models showed no
detectable difference between mass and targeted treatment strategies on prevalence
reduction in school-aged children for S. mansoni (odds ratio 0.47, 95%CI 0.13–1.68, p =
0.227) and S. haematobium (0.41, 95%CI 0.06–3.03, p = 0.358). Box plots also showed no
apparent differences in intensity reduction between the two treatment strategies.
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Conclusions/Significance
The results of this meta-analysis do not support the hypothesis that community-wide treat-
ment is more effective than targeted treatment at reducing schistosomiasis infections in chil-
dren. This may be due to the relatively small number of included studies, insufficient
treatment coverage, persistent infection hotspots and unmeasured confounders. Further
field-based studies comparing mass and targeted treatment are required.
Author summary
Schistosomiasis is a neglected tropical disease, caused by parasitic worms, that affects
more than 143 million people worldwide. Chronic infections can lead to significant
morbidity including kidney damage, anaemia, malnutrition, infertility and growth
impairment. School-aged children between six and 15 years are often targeted for regular
treatment with praziquantel in large-scale drug delivery programs, because they suffer a
disproportionate burden of morbidity. On the other hand, a mass drug delivery strategy
that treats all members of the community has been suggested in a move towards elimina-
tion of schistosomiasis as a public health problem. In this systematic review, we assess the
impact of community-wide versus children-only praziquantel distribution in reducing
schistosomiasis infections in school-aged children. We did not detect a difference between
mass and targeted treatment strategies, possibly due to factors including insufficient treat-
ment coverage and persistent sources of reinfection. Addressing these factors may assist
in optimising control programs.
Introduction
Schistosomiasis is a water-borne neglected tropical disease (NTD) that infects an estimated
143 million people worldwide [1]. Its global disease burden is estimated at 2.5 million disabil-
ity-adjusted life years, and 220 million people across 52 countries live in areas endemic for
schistosomiasis [1, 2]. The disease is caused by parasitic trematodes of the Schistosoma genus,
hosted in freshwater Bulinus snails, and manifests in intestinal (Schistosoma mansoni, Schisto-
soma japonicum, Schistosoma mekongi, Schistosoma guineensis and Schistosoma intercalatum)
and urogenital (Schistosoma haematobium) forms [3]. Transmission occurs when infected
individuals contaminate freshwater sources with faeces or urine containing parasite eggs. The
eggs hatch, releasing miracidia into the water that penetrate the host snails and develop into
infective cercariae. The cercariae are released from the snails and infect humans by penetrating
the skin during contact with contaminated water [4]. Infection is often endemic in rural agri-
cultural or fishing populations with poor sanitation [4]. Chronic infections cause significant
morbidity including renal damage, anaemia, malnutrition, infertility and poor physical and
cognitive development. Less frequently they can cause fatal complications from renal failure,
portal hypertension and bladder cancer [4].
Praziquantel, a broad-spectrum anthelminthic, has been used for over 40 years as the cor-
nerstone of schistosomiasis control, due to its safety, low cost and efficacy against all Schisto-
soma species [5, 6]. The World Health Organization (WHO) recommends that school-aged
children in endemic areas are treated either annually (if prevalence is above 50% in school-
aged children), every two years (if prevalence is between 10% and 49% in school-aged chil-
dren), or upon entering and leaving primary school (if prevalence is lower than 10% in school-
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aged children) [5]. The WHO recommendations additionally suggest treating special groups
of at-risk adults if schistosomiasis prevalence is above 10% in school-aged children, and entire
communities if prevalence in school-aged children is above 50% [5, 7]. In the WHO’s land-
mark roadmap for NTD control, released in 2012, schistosomiasis control targets focus exclu-
sively on school-aged children [8]. By 2020, the WHO target is that 75% of school-aged
children at risk of schistosomiasis should be receiving regular praziquantel [8]. This target was
set because the donations of praziquantel were sufficient to cover only this age group [9], and
the WHO wanted to indicate an attainable goal for 2020. Globally, 68% of at-risk school-aged
children received praziquantel in 2017, while coverage of at-risk adults was much lower at
16.9% [2].
With calls for elimination of schistosomiasis as a public health problem, defined by the
WHO as less than 1% prevalence of heavy-intensity infections among school-aged children [7,
10], the effectiveness of treatment targeted to children has been called into question [11, 12]. It
has been suggested that treatment should instead be delivered community-wide, to reduce dis-
ease prevalence and transmission to children from other vulnerable members in the commu-
nity [12, 13], and minimise persistent untreated populations that can significantly impact on
the success of control programs [14]. Results from mathematical modelling suggest that
“mass” (community-wide) treatment is more effective for controlling schistosome infection
than a “targeted” (children-only) program; however, this is dependent on local epidemiologi-
cal settings, including pre-control burden in adults, school enrolment rates, and transmission
intensity [14]. Additionally, although the outright cost of administering treatment to the entire
community is higher than treating school-aged children only, modelling has shown commu-
nity-wide drug administration to be a highly cost-effective strategy across different prevalence
settings [15]. With many child-targeted programs being conducted through schools, commu-
nity-wide treatment strategies would have the added benefit of increasing treatment coverage
of non-enrolled school-aged children [16].
The Schistosomiasis Consortium for Operational Research and Evaluation (SCORE) has
been established to answer strategic questions about schistosomiasis control and elimination.
A number of trials have been implemented to assess the effectiveness of different control strat-
egies in reducing the burden of active infection [17–21]. The results of these trials have been
inconsistent, with some studies finding that community-wide treatment is more effective at
reducing schistosome prevalence [22], whereas others report no significant difference between
community-wide and child-targeted treatment [17, 20, 21].
To our knowledge, there is no systematic synthesis comparing mass and targeted delivery
strategies (see Box 1) for schistosomiasis control in terms of their impact on schistosomiasis
Box 1. Definitions of “mass” and “targeted” drug delivery in this
paper
Throughout this paper, we refer to “mass” and “targeted” drug delivery strategies, as
defined by the World Health Organization:
Mass drug administration: the entire population of a given area is given anthelminthic
drugs at regular intervals, irrespective of the individual infection status [23]. This is also
known as community-wide treatment.
Targeted drug administration: specific risk groups in the population (defined by age,
sex or other social characteristic) are treated at regular intervals, irrespective of infection
status [23]. For the purposes of this paper, targeted drug administration refers to treat-
ment targeted specifically to children.
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prevalence and intensity among children. This systematic review and meta-analysis aims to
address this gap. Specific aims of this study are: (a) to summarise existing literature reporting
the effects of mass and targeted praziquantel distribution on schistosomiasis prevalence and
intensity in school-aged children, and (b) to examine the differential effect of mass and tar-
geted praziquantel delivery on schistosomiasis prevalence and intensity in school-aged
children.
Methods
Search strategy and selection criteria
This systematic review and meta-analysis was conducted according to PRISMA guidelines
[24] (see S1 Checklist) and is available in PROSPERO, registration number CRD42018095377.
Eligible studies were those that reported prevalence or intensity of schistosomiasis (any or all
species) infection, before and after mass or targeted delivery of praziquantel. We included lon-
gitudinal studies as well as repeated cross-sectional studies in this review. Randomised con-
trolled trials were included when randomisation was performed at the community or school
level. There was no restriction on date or language of publication, geographical area, or length
of study.
Studies were excluded if: treatment was delivered only to infected individuals; positive indi-
viduals were re-treated shortly after initial drug administration; all follow-up intervals (defined
as the time between drug administration and examination) fell outside of a two month to
18-month timeframe; treatment intervals or follow-up times were not provided; or the drug
administration strategy changed (from mass to targeted or vice versa) during the study with
no interim data reported. Studies were excluded from quantitative analysis if they did not
report initial and/or follow-up sample sizes.
We searched for studies through the databases MEDLINE, Embase and Web of Science on
15 February 2019. The following search terms were used: (a) disease-related terms: “Schistoso-
miasis” or “Bilharzia” or “Schistosoma” or “Schistosoma mansoni” or “Schistosoma haemato-
bium” or “Schistosoma japonicum” or “Schistosoma mekongi” or “Schistosoma guineensis” or
“Schistosoma intercalatum” or “Schistosome” or “Blood flukes” or “Trematode” or “Trema-
toda” or “Trematode infections” or “Trematode worms”, and (b) intervention-related terms:
“Praziquantel” or “PZQ” or “Drug therapy” or “Chemotherapy” or “Preventive chemotherapy”
or “Mass drug administration” or “Community based treatment” or “School based treatment”.
The complete search strategy can be found in S1 Appendix. Additional studies were identified
by hand-searching relevant review paper reference lists [14, 16, 25–31], monitoring the
SCORE publication list, and contacting experts in the field.
Following de-duplication, studies were screened by title and abstract, followed by retrieval
of full-text articles. All full-texts were then screened for eligibility against the study protocol.
Articles published in English were examined by DMC and NEC. Articles published in lan-
guages other than English were screened by researchers fluent in those languages.
Data extraction
Data were extracted from included studies by DMC and verified by NEC. Extracted data
included initial and follow-up prevalence and intensity of the reported Schistosoma species;
study location, design and duration; drug administration strategy (mass or targeted); drug
administration platform (school-based, fixed community site or mobile community drug dis-
tributors); drug dose; number of treatment rounds; treatment interval(s); treatment coverage;
diagnostic method; and interval between drug administration and follow-up.
Impact of praziquantel delivery on schistosomiasis in school-aged children
PLOS Neglected Tropical Diseases | https://doi.org/10.1371/journal.pntd.0007808 October 11, 2019 4 / 20
Where studies reported multiple treatment arms with different treatment or follow-up
intervals, data from each study arm were extracted. In studies with a control group that
received drug treatment only and groups with additional interventions (e.g. health education),
only data from the control group were extracted.
We contacted nine authors to request additional information, including aggregated follow-
up prevalence and intensity data, follow-up interval, initial and follow-up sample sizes, prazi-
quantel dose and interim prevalence data when delivery strategies changed during the study.
Additional data on the number of infected individuals and intensity of infection were received
from one study [21].
Study quality was assessed using a modified version of a validated scale designed to assess
risk of bias in prevalence studies [32], as reported previously [26]. Studies were assessed against
nine criteria encompassing internal and external validity.
Statistical analysis
Analyses were performed using a similar methodology to our previously-reported meta-analy-
sis comparing mass and targeted drug delivery strategies for soil-transmitted helminth infec-
tions [26]. All analyses were performed separately for each Schistosoma species.
To examine the impact of mass and targeted treatment on schistosome prevalence, an
inverse variance weighted generalised linear model with robust error variances was used, in
order to adjust for a number of key sources of heterogeneity. The covariates for the model
were: drug administration strategy (mass or targeted); baseline prevalence; number of treat-
ment rounds between baseline and follow-up; and follow-up interval (i.e., time between final
treatment round and follow-up prevalence assessment). Treatment coverage was not included
in the primary model because it was not reported in a large number of studies.
Where age-stratified prevalence was not available (two studies [33, 34]), infection preva-
lence in school-aged children was estimated from community prevalence using scaled age
weights reported elsewhere [35]. The first reported assessment of infection prevalence and
intensity was used as the baseline for all studies except one, where interim data were used as
baseline because data were combined for study arms receiving treatment at different intervals
for the first two years of the study [34]. Where multiple rounds of treatment were reported in
one study, prevalence and intensity at the final follow-up were used. Where multiple follow-up
intervals were reported, the closest to 12 months was used. Some studies were entered into the
model multiple times to account for multiple species and strategies (mass or targeted) being
reported [17, 21, 22, 36–41].
The outcome variable for the model was prevalence reduction (PReduc). This was defined
as (p1-p2)/p1 = 1 –prevalence ratio, where p1 is the initial prevalence proportion and p2 is the
post-treatment prevalence proportion. P2/p1 is the prevalence ratio (PRatio). As described pre-
viously, PReduc was truncated so that any increase between initial prevalence and follow-up
prevalence would be reset to zero [26]. Coefficients were exponentiated to generate weighted
odds ratios. Any study weights that were more than five times greater than the upper quartile
were truncated and substituted with the threshold weight.
A secondary analysis was performed to pool prevalence reduction for each Schistosoma spe-
cies. This was done by pooling PRatio, but results are reported as 1 –PRatio = PReduc (non-
truncated). Results from each study were pooled using the inverse variance heterogeneity
model [42]. Heterogeneity was assessed using Cochran’s Q and Higgins’ I2, with I2 greater
than 50% indicating significant heterogeneity. Small-study effects were examined using Egger’s
regression test (two-tailed p<0.1 indicating of asymmetry).
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A number of sensitivity analyses were performed. Firstly, we added a covariate for reported
treatment coverage (categorised as average of 75% coverage or greater across all treatment
rounds; average of below 75% coverage across all treatment rounds; or treatment coverage not
reported) to the generalised linear model. Secondly, we re-ran the generalised linear model
excluding studies that reported greater than 50% initial prevalence, the cut-off for high-
endemicity zones [5]. Finally, we re-ran the generalised linear model including follow-up prev-
alence measured after one treatment round (or closest), rather than after the final treatment
round. Additionally, the generalised linear model and secondary meta-analysis were re-run
using random effects model weights for comparison.
To compare intensity reduction between mass and targeted studies, given that limited data
were available, simple box plots of egg reduction rates were created separately for mass and tar-
geted studies. The box plots were weighted by sample size under the assumption that larger
weights designate more accurately measured intensity reductions. Because there were insuffi-
cient studies to adjust for number of treatment rounds in this analysis, intensity reduction was
calculated after one round of treatment (or closest) for consistency. Egg reduction rate was cal-
culated using mean infection intensity at baseline and follow-up for each study, as follows: Egg
reduction rate = (Mean intensitybaseline−Mean intensityfollowup)/(Mean intensitybaseline).
All meta-analyses were performed using MetaXL version 5.3 (Epigear International, Noosa,
Australia). To run the generalised linear models and create the weighted box plots, Stata ver-
sion 15.1 (StataCorp, College Station, TX, USA) was used.
Results
After running the search terms and removing duplicate entries, 9,249 articles were considered
for the systematic review process. An additional 10 studies were added through reference list
searches. Thirty-four studies met the inclusion criteria for the systematic review. Of these, 28
studies were included for meta-analysis. The screening and selection process is illustrated in
Fig 1. A summary of all included studies can be found in Table 1 and S1 Table.
Characteristics of included studies
Of the 34 included studies, 13 (38.2%) reported on only S. mansoni, 12 (35.3%) reported on only
S. haematobium, seven (20.6%) reported on both S. mansoni and S. haematobium, and two (5.9%)
reported on S. japonicum (Table 2). For S. mansoni, nine of 20 studies (45.0%) used a mass drug
administration strategy and 14 (70.0%) used a targeted strategy. Three of these studies (15.0%)
reported both strategies. For S. haematobium, seven of 19 studies (36.8%) used a mass drug
administration strategy and 14 (73.7%) used a targeted strategy. Two of these studies (10.5%)
reported both strategies. Of the five studies that included both mass and targeted strategies, three
of these were randomised controlled trials that compared mass and targeted treatment arms
within the study [17, 20, 21], one study used baseline village prevalence to direct mass or targeted
treatment [36], and one study presented results for individual village groups that adopted mass or
targeted strategies [22]. Both studies of S. japonicum reported mass drug administration.
As shown in Table 2, studies of targeted drug distribution primarily used a school-based
platform to treat school-aged children. Some studies additionally used other platforms to
reach non-enrolled school-aged children, including fixed community sites at dispensary units
and mobile community drug distributors. One study compared school-based and community-
based drug delivery for school-aged children [39], and one study treated only preschool chil-
dren, aged two to six years [55]. Two studies did not report delivery platform [36, 55]. Studies
of mass drug distribution primarily conducted drug administration through mobile
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community drug distributors. Fixed community sites and schools were also used to distribute
drugs to the entire community. Six studies did not report the delivery platform [33, 34, 36, 45,
54, 62].
Fig 1. Process of selection of studies for inclusion in this synthesis.
https://doi.org/10.1371/journal.pntd.0007808.g001
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Table 1. Characteristics of included studies for systematic review.
Author & year Reference Location Drug delivery
strategy
Treatment rounds prior
to final follow-up
Follow-up interval after
last treatment round
Study design Drug delivery platform
(s)
Schistosoma mansoni
Abudho et al.,
2018�
[43] Kenya Targeted 4 rounds, yearly 12 months Repeated cross-
sectional
School
Ahmed et al.,
2012�
[44] Sudan Targeted 1 round 12 months Longitudinal School
Al Abaidani et al.,
2016�
[45] Oman Mass 4 rounds, yearly 12 months Repeated cross-
sectional
Not reported
Assare et al.,
2016�
[18] Cote d’Ivoire Targeted 1 round 11 months RCT
SCORE
School
Boisier et al.,
1998�
[34] Madagascar Mass 4 rounds, yearly
or 6 rounds, biannually
(final round annual)
12 months Longitudinal Not reported
Hodges et al.,
2012�
[46] Sierra Leone Targeted 1 round 6 months Repeated cross-
sectional
School
Kaatano et al.,
2015
[47] Tanzania Mass 4 rounds, yearly 12 months Repeated cross-
sectional
School, fixed community
site, mobile CDDs
Karanja et al.,
2017�
[19] Kenya Targeted 2 or 4 rounds, yearly or
biennially
12, 24 and 36 months RCT
SCORE
School
Mwinzi et al.,
2012�
[48] Kenya Mass 1 round 6 months Repeated cross-
sectional
Mobile CDDs
Olsen et al., 2018� [21] Tanzania Both 2 or 4 rounds, yearly or
biennially
12, 24 and 36 months RCT
SCORE
School, fixed community
site
Onkanga et al.,
2016
[20] Kenya Both 2 rounds, yearly 12 months RCT
SCORE
School, mobile CDDs
Wanjala et al.,
2013�
[49] Kenya Targeted 1 round 18 months Longitudinal School
Zhang et al., 2007� [22] Uganda Botb 2 rounds, yearly 12 months Longitudinal School, mobile CDDs
Both Schistosoma mansoni and Schistosoma haematobium
Brinkmann et al.,
1988�
[36] Mali Both 1 round 12 months Repeated cross-
sectional
Not reported
Koukounari et al.,
2007�
[37] Burkina Faso Targeted 1 round 12 months Longitudinal School, fixed community
site, mobile CDDs
Landoure et al.,
2012�
[38] Mali Mass 3 or 4 rounds, yearly (with
1 year break)
12 and 24 months Repeated cross-
sectional
School, mobile CDDs
Massa et al., 2009� [39] Tanzania Targeted 1 round 12 months Repeated cross-
sectional
School, mobile CDDs
Mwandawiro
et al., 2019�
[40] Kenya Targeted 2 or 4 rounds, yearly 12 months Repeated cross-
sectional
School
Ouedraogo et al.,
2016
[50] Burkina Faso Targeted 4 rounds, approximately
biennially
12 or 24 months Repeated cross-
sectional
School, fixed community
site, mobile CDDs
Toure et al., 2008� [41] Burkina Faso Targeted 1 round 12 and 24 months Longitudinal School, fixed community
site, mobile CDDs
Schistosoma haematobium
Adewale et al.,
2018�
[51] Nigeria Targeted 1 round 12, 24, 36, 48 and 60
months
Longitudinal School
Chaula & Tarimo,
2014�
[52] Tanzania Targeted 2 rounds, yearly 12 months Longitudinal School
Garba et al., 2004� [33] Niger Mass 1 round 10 and 28 months Repeated cross-
sectional
Not reported
Hopkins et al.,
2002
[53] Nigeria Mass 2 rounds, yearly 12 months Repeated cross-
sectional
Mobile CDDs
(Continued)
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Table 1. (Continued)
Author & year Reference Location Drug delivery
strategy
Treatment rounds prior
to final follow-up
Follow-up interval after
last treatment round
Study design Drug delivery platform
(s)
Janitschke et al.,
1989�
[54] Yemen Mass 1 round 12 months Repeated cross-
sectional
Not reported
Mduluza et al.,
2001�
[55] Zimbabwe Targeted 7 rounds, bi-monthly 2 months Longitudinal Not reported
N’Goran et al.,
2001�
[56] Cote d’Ivoire Targeted 1 round or 2 rounds,
yearly
6, 12, 18 and 24 months Longitudinal School
Pennance et al.,
2016�
[57] Tanzania Mass 4 rounds, biannually 7–8 months Repeated cross-
sectional
School, mobile CDDs
Phillips et al.,
2017�
[17] Mozambique Both 2 or 4 rounds, yearly or
biennially
12, 24 and 36 months RCT
SCORE
School, fixed community
site, mobile CDDs
Saathoff et al.,
2004�
[58] South Africa Targeted 1 round 3, 16, 41 and 53 weeks Longitudinal School
Shehata et al.,
2018�
[59] Zambia Targeted 1 round 6 and 12 months Longitudinal School
Stothard et al.,
2009�
[60] Tanzania Targeted 2 rounds, yearly 12 months Repeated cross-
sectional
School
Schistosoma japonicum
Lin et al., 1997 [61] China Mass 2 rounds, yearly 12 months Longitudinal Fixed community site
Zhang et al., 1998 [62] China Mass 1 round 12 months Longitudinal Not reported
RCT = randomised controlled trial, SCORE = study conducted by Schistosomiasis Consortium for Operational Research and Evaluation, CDD = community drug
distributor
�Included in meta-analysis
https://doi.org/10.1371/journal.pntd.0007808.t001
Table 2. Descriptive indicators separated by schistosome species.
S. mansoni
(n = 20�)
S. haematobium
(n = 19�)
S. japonicum
(n = 2)
Mass Targeted Mass Targeted Mass
Drug delivery strategy 9 (45%)^ 14 (70%)^ 7 (37%)^ 14 (74%)^ 2 (100%)
Delivery platform#
School 2 (22%) 14 (100%) 2 (29%) 12 (86%) -
Community–fixed site 2 (22%) 3 (21%) 1 (14%) 3 (21%) 1 (50%)
Community–mobile unit 5 (56%) 4 (29%) 4 (57%) 4 (29%) -
Not reported 3 (33%) - 3 (43%) 2 (14%) 1 (50%)
Number of treatment rounds†
1 round 3 (33%) 8 (57%) 3 (43%) 8 (57%) 2 (100%)
Multiple rounds 7 (78%) 7 (50%) 5 (71%) 8 (57%) -
Follow up after final treatment round†
Less than 12 months 1 (11%) 2 (14%) 2 (29%) 6 (43%) -
12 months 8 (89%) 11 (79%) 4 (57%) 13 (93%) 2 (100%)
Greater than 12 months 2 (22%) 6 (43%) 4 (57%) 9 (64%) -
� These totals include seven studies that report both S. mansoni and S. haematobium.
^ Three studies for S. mansoni and two studies for S. haematobium reported both mass and targeted strategies
# Numbers add to greater than 100% because studies used more than one delivery platform.
† Number of treatment rounds and follow up after final treatment round may add to greater than 100% as this incorporates studies that have multiple treatment arms
with differing values for these variables.
https://doi.org/10.1371/journal.pntd.0007808.t002
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The number of treatment rounds varied from one to seven rounds, with treatment intervals
ranging from two to 24 months. The follow-up interval after the final treatment round ranged
from three weeks to 60 months. The most common follow-up interval after the final treatment
round for all three species and both drug administration strategies was 12 months (27 studies,
79.4%).
Nine potential deficiencies were assessed in terms of risk of bias (S2 Table). The most com-
mon deficiencies were a response rate of less than 75% (or not reported) in 31 studies and pra-
ziquantel not delivered to at least 75% of the population (or not reported) in 19 studies. All
other deficiencies were less common.
All 22 studies of S. mansoni and S. japonicum used stool samples to determine infection
prevalence and intensity; all used the Kato-Katz diagnostic method. All 19 S. haematobium
studies used urine samples to determine infection prevalence and intensity. Seventeen studies
(89.5%) used the urine filtration method and four studies (21.1%) used urine dipsticks; two of
these studies (10.5%) used both methods.
As shown in S1 Table, the most common additional medication was albendazole (11 stud-
ies, 32.4%), with mebendazole (two studies, 5.9%) and ivermectin (one study, 2.9%) also
administered. Twenty-one studies (61.8%) reported no additional medications. Health educa-
tion (e.g. videos, posters, broadcasts, reading material) was reported in seven studies (20.6%).
Snail control using tilapia fish or molluscicide (two studies, 5.9%) and water source improve-
ments with pumped wells (one study, 2.9%) were also reported. Twenty-seven studies (79.4%)
reported no additional interventions apart from drug delivery.
Most studies were conducted in Africa (30 studies, 88.2%), with two studies (5.9%) in the
Middle East and two studies in Asia. Tanzania and Kenya (six studies (17.6%) each) were the
most commonly studied countries. Fourteen studies (41.2%) used a longitudinal design, while
15 (44.1%) were repeated cross-sectional studies and five were randomised controlled trials
conducted by SCORE.
Treatment coverage was reported in 20 of 34 studies (58.8%), ranging from 22.7% to
129.8% (see S1 Table). Coverage values over 100% were seen due to inaccurate estimates of
population size. Sixteen of these studies (80.0%) reported coverage greater than 75% for at
least one treatment round.
Schistosome prevalence was reported in all included studies, while a measure of infection
intensity was reported in 30 of the 34 studies (88.2%). Four of these studies reported only the
proportion of high intensity infections, and two studies reported intensity only at baseline.
Quantitative analysis
Only S. mansoni and S. haematobium had sufficient studies to perform quantitative analysis.
Results from the inverse variance weighted generalised linear model are shown in Table 3.
For S. mansoni, 19 studies were included in the model, with two studies including two treat-
ment arms [21, 22]. There was no significant difference in prevalence reduction following
mass versus targeted treatment (odds ratio (OR) 0.47, 95% confidence interval (CI) 0.13–1.68,
p = 0.227). Number of treatment rounds, baseline prevalence and follow-up time were not sig-
nificantly associated with prevalence reduction.
Similarly, for S. haematobium, 19 studies were included in the model, with two studies
including two treatment arms [17, 36]. There was no significant difference between mass and
targeted drug treatment (OR 0.41, 95% CI 0.06–3.03, p = 0.358). Baseline prevalence, number
of treatment rounds, and follow-up time were not significantly associated with prevalence
reduction.
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Results for intensity reduction are presented in Fig 2. There are no apparent differences in
median egg reduction rates between mass and targeted praziquantel delivery for either S. man-
soni or S. haematobium.
In sensitivity analyses, adding a covariate for treatment coverage did not significantly affect
the results of the generalised linear model (S3 Table). Furthermore, results remained generally
robust when high-prevalence studies were excluded and when follow-up prevalence was mea-
sured after one treatment round or closest (S4 Table). For S. haematobium, when studies with
greater than 50% baseline prevalence were excluded, only a very small number of studies
remained, leading the model to become unstable with very wide confidence intervals.
Results of the secondary meta-analyses synthesising the non-truncated prevalence reduc-
tion estimates from individual studies are shown in Table 4. Pooled prevalence reduction is
Table 3. Odds ratio of prevalence reduction� for selected covariates, stratified by Schistosoma species (inverse var-
iance weighted generalised linear model with robust error variance).
Odds ratio (95% CI) p-value R2
Schistosoma mansoni
Mass (n = 7) vs targeted (n = 12) treatment 0.47 (0.13–1.68) 0.227 0.126
Baseline prevalence (%) 1.02 (0.99–1.05) 0.292
Number of treatment rounds 0.95 (0.64–1.42) 0.786
Follow-up time (months) 1.06 (0.92–1.23) 0.390
Schistosoma haematobium
Mass (n = 6) vs targeted (n = 13) treatment 0.41 (0.06–3.03) 0.358 0.279
Baseline prevalence (%) 0.99 (0.95–1.05) 0.926
Number of treatment rounds 0.76 (0.49–1.20) 0.219
Follow-up time (months) 1.48 (0.50–4.40) 0.452
� Prevalence reduction = (Prevalencefollow-up−Prevalencebaseline) / Prevalencebaseline, truncated such that any
prevalence increase was reset to zero
https://doi.org/10.1371/journal.pntd.0007808.t003
Fig 2. Boxplots of infection intensity reduction for S. mansoni (A) and S. haematobium (B) for studies using mass and targeted strategies. Studies were weighted
according to their sample size.
https://doi.org/10.1371/journal.pntd.0007808.g002
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shown separately for mass and targeted studies, stratified by number of treatment rounds.
There was significant heterogeneity among included studies. In targeted studies, I2 was 96.7%
for S. mansoni and 98.5% for S. haematobium. In mass studies, I2 was 93.3% for S. mansoni
and 98.6% for S. haematobium.
The results of analyses conducted using random effects weights are depicted in S5 Table
and S6 Table. Re-analysis using this approach did not significantly affect study results. In
terms of small study effects, Egger’s regression showed evidence of mild funnel plot asymmetry
for S. mansoni (intercept -4.10, p = 0.022), but not for S. haematobium (intercept -3.03,
p = 0.335).
Discussion
Treatment of schistosomiasis has been scaled up over the last decade from test-and-treat strat-
egies towards large-scale preventive drug administration programs. Recent modelling studies
predict community-wide treatment programs to be the most effective strategy for controlling
infection [14, 15]. To our knowledge, this systematic review and meta-analysis is the first syn-
thesis of its kind, comparing the effects of mass and targeted delivery strategies on schistosomi-
asis prevalence and intensity in school-aged children.
The results of this analysis show that based on currently published studies, there is no
detectable difference between mass and targeted drug administration strategies on the reduc-
tion in S. mansoni or S. haematobium infection prevalence or intensity in school-aged chil-
dren. This does not align with our hypothesis, which was supported by previously-published
mathematical modelling predictions [14] and a similar meta-analysis on soil-transmitted hel-
minths [26]. The current analysis reflects only the findings of the 28 studies that were consid-
ered, including recent cluster-randomised controlled trials conducted by the SCORE initiative
that found community-wide and child-targeted treatment equally effective in reducing preva-
lence in S. mansoni and S. haematobium infections [17, 20, 21]. An earlier study that applied
either mass or targeted treatment to different villages also found similar prevalence reductions
following mass and targeted drug delivery for S. haematobium [36].
One of the most plausible reasons for these results is insufficient treatment coverage in
mass drug administration programs. Compared to child-targeted programs conducted
through schools, mass drug administration programs may face more challenges in reaching a
majority of the population eligible for treatment. Many studies included in our review did not
Table 4. Meta-analysis results showing pooled prevalence reduction estimates (non-truncated), shown for mass and targeted studies for each schistosome species,
stratified by number of treatment rounds.
Delivery method Number of treatment rounds PReduc� (95% CI) Cochran’s Q p value (Cochran’s Q) Number of study datasets
Schistosoma mansoni
Mass One round 0.22 (-0.76–0.66) 27.63 <0.001 4
Multiple rounds 0.34 (0.07–0.53) 36.55 <0.001 3
Targeted One round 0.41 (0.19–0.57) 84.34 <0.001 7
Multiple rounds 0.33 (-0.33–0.67) 235.49 <0.001 5
Schistosoma haematobium
Mass One round 0.57 (0.24–0.75) 46.86 <0.001 3
Multiple rounds 0.34 (-0.04–0.58) 111.41 <0.001 3
Targeted One round 0.69 (0.45–0.82) 216.34 <0.001 7
Multiple rounds 0.60 (-0.01–0.84) 574.68 <0.001 6
�PReduc = (Prevalencefollow-up−Prevalencebaseline) / Prevalencebaseline
https://doi.org/10.1371/journal.pntd.0007808.t004
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report treatment coverage, and among those that did, reported coverage varied widely between
studies, and was often inconsistent across treatment rounds within studies. Due to the large
amount of studies that did not report treatment coverage, we were unable to adjust for this in
our primary analysis. However, our findings for mass versus targeted treatment did not change
when we conducted a sensitivity analysis controlling for treatment coverage. Further issues
with reported treatment coverage are that underestimation of the target population is common
and leads to an overestimation of treatment coverage [20], and also that there may be consider-
able discrepancies between reported treatment coverage (those who receive tablets) and treat-
ment compliance (those who actually ingest the tablets) [63]. Compliance is an important
consideration when reporting treatment coverage; however, there is considerable heterogene-
ity in the defining and reporting of treatment compliance in existing literature [63].
Another potential explanation for our findings is that in some settings, school-aged chil-
dren may play a dominant role in driving transmission. Infections peak in childhood, leading
school-aged children to generally carry more infection than other community members [4].
Therefore, in some settings, expanding treatment programs to other community members
may not have a detectable effect on transmission among school-aged children. Furthermore, it
is known that in many settings, there are hotspots of infection that have a disproportionate
influence on driving transmission [64]. These persistent low-prevalence populations tend to
remain, regardless of the drug administration strategy or how well drug administration pro-
grams are implemented [57]. Such hotspots may explain why significant differences between
mass and targeted treatment were not evident in this review.
Several limitations in this study must be acknowledged. Firstly, only a relatively small num-
ber of studies were included in meta-analysis, especially for mass treatment. Secondly, there is
potential for confounding from factors we were unable to include in our model, such as water,
sanitation and hygiene (WASH) conditions, socioeconomic status and treatment coverage. An
important potential confounder is the proximity of the infected population to local contami-
nated bodies of water [22], and the frequency and duration of water contact, especially in chil-
dren [18]. Several studies have shown that populations living closer to local water bodies are
more likely to have a higher prevalence and rate of reinfection [19, 22, 65]. Thirdly, limitations
of existing diagnostic techniques for identifying schistosome infections may have affected our
findings. Both the Kato-Katz technique (used to diagnose for S. mansoni and S. japonicum
infections) and urine filtration (used for S. haematobium); are known to have low sensitivity,
particularly for detecting light-intensity infections in areas with low endemicity [66, 67]. This
is a source of measurement error that can underestimate the actual prevalence of infection in a
population, creating a non-differential misclassification and potentially biasing findings
towards the null hypothesis. Finally, two included studies did not have age-stratified data avail-
able, so we used standardised weights for calculating prevalence in school-aged children.
These weights were taken from a study published in 1998 [35]. The age distribution and schis-
tosome prevalence may vary between communities and prevalence reduction among school-
aged children may not reflect that of other age groups.
Our review focuses on the impact of mass and targeted drug delivery strategies on school-
aged children, who are recognised as the group at highest risk of schistosomiasis-associated
morbidity. However, it is important to note that expanding control programs community-
wide would provide the advantage of reducing morbidity in other age groups (i.e., preschool-
aged children, adolescents, and adults), in whom the burden of schistosomiasis-associated
morbidity may also be significant [68, 69]. WHO guidelines currently do not recommend a
baseline assessment of infection prevalence and intensity in age groups other than school-aged
children [70]. However, recent mathematical modelling highlights that including a broader
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range of age groups in baseline assessments, as well as ongoing monitoring, is important in
order to determine appropriate control strategies for defined regions [71].
Although current targets, drug donations, and operational guidelines for schistosomiasis
control focus on school-aged children [8, 9, 23], the burden of schistosomiasis among both
adults and preschool-aged children has been acknowledged [5, 72]. At-risk adults are recom-
mended to receive regular praziquantel in certain epidemiological settings [5], although global
coverage remains low [2]. On the other hand, preschool-aged children are not included in
WHO guidelines for schistosomiasis control because the safety of praziquantel in children
under 4 years of age has not been established, and because there is no suitable paediatric for-
mulation available [72, 73]. A recent dose-ranging study identified that a single 40mg/kg dose
of praziquantel can be administered safely and efficaciously in children under 5 years of age
[73], and a paediatric formulation of praziquantel is currently in development [74]. Treatment
of preschool-aged children could be achieved by utilising existing platforms, such as child
health days, as is done for other NTDs [75], if this formulation was made available free of
charge.
Our findings highlight the importance of additional strategies beyond regular drug admin-
istration in achieving community-wide control of schistosomiasis. Praziquantel remains effec-
tive at treating S. mansoni and S. haematobium [76], but due to ongoing environmental
reservoirs of disease, it does not stop reinfection. Rapid reinfection can occur in endemic areas
[77], indicating that treatment should be accompanied with WASH interventions to improve
water and sanitation conditions and hygiene behaviours. These interventions may include pro-
vision of a safe water supply, education to end open defecation, and safe contact with contami-
nated bodies of water [78]. As schistosomiasis is transmitted to humans through contact with
contaminated freshwater snails, and amplification of parasite numbers occurs within the inter-
mediate host [4], snail control with molluscicide or similar treatment should also be consid-
ered [79]. Only a very small number of studies in this review included such strategies.
In conclusion, although our analysis of current literature does not agree with mathematical
modelling findings, there are limitations to existing studies and to this meta-analysis. There
are further cluster-randomised controlled trials comparing strategies in development (C. King
and A. Amadou, personal communication), which will provide more information on the effect
of mass versus targeted treatment. Despite the findings presented here, it is nonetheless likely
that mass treatment–when delivered with high coverage rates–will be more beneficial in some
settings than targeted treatment for reducing infections among school-aged children. More
research is needed to address issues with achieving coverage targets, implementation of
WASH improvements, and addressing disease hotspots and sources of rapid reinfection. Con-
sideration of these factors will assist with optimising control programs in the push towards
eliminating schistosomiasis as a public health problem.
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